NewAmsterdam Pharma Co N.V.
Nasdaq · Healthcare · Pharmaceutical Preparations · Narrden, Netherlands
NAMS chart
What traders are saying about $NAMS
Latest postsNewAmsterdam Pharma Co N.V. news
- $NAMS stock is down 11% today. Here's what we see in our data.
Quiver Quantitative ·
- Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
Yahoo Finance ·
- Group 1 Automotive and 4 More Stocks See Action From Activist Investors
Yahoo Finance ·
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
Yahoo Finance ·
- NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
Yahoo Finance ·
- NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Yahoo Finance ·
- NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
Yahoo Finance ·
- Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Yahoo Finance ·
- How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Yahoo Finance ·
- Novartis Trial Failure Sparks Biopharma Options Frenzy
Yahoo Finance ·
- NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
Yahoo Finance ·
NewAmsterdam Pharma Co N.V. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M |
| Net income | -$203.0M | -$242.0M | -$177.0M | -$22.6M |
| Diluted EPS | $-1.72 | $-2.56 | $-2.15 | $-1.19 |
| Total assets (year end) | $769.3M | $864.6M | $347.1M | $478.5M |
| Cash and equivalents (year end) | $490.0M | $771.7M | $340.4M | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About NewAmsterdam Pharma Co N.V.
- Ticker
- NAMS (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Narrden, Netherlands
- Incorporated in
- Netherlands
- Fiscal year end
- December 31
- SEC CIK
- 1936258
- Former names
- NewAmsterdam Pharma Co B.V.
Frequently asked questions
What exchange is NewAmsterdam Pharma Co N.V. listed on?
NewAmsterdam Pharma Co N.V. trades on the Nasdaq under the ticker symbol NAMS.
What industry is NewAmsterdam Pharma Co N.V. in?
NewAmsterdam Pharma Co N.V. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is NewAmsterdam Pharma Co N.V. headquartered?
NewAmsterdam Pharma Co N.V.'s business address on file with the SEC is in Narrden, Netherlands.
When does NewAmsterdam Pharma Co N.V.'s fiscal year end?
NewAmsterdam Pharma Co N.V.'s fiscal year ends on December 31.
How much revenue did NewAmsterdam Pharma Co N.V. report?
NewAmsterdam Pharma Co N.V. reported $22.5M in revenue for calendar year 2025, according to its SEC filings.